# BridgeBio (BBOT) — News

BBOT · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/bbot/news

## Recent headlines

- [Encaleret increased bone turnover and improved participant-reported symptoms in the phase 3 Calibrate trial in ADH1](https://www.ainvest.com/news/encaleret-increased-bone-turnover-improved-participant-reported-symptoms-phase-3-calibrate-trial-adh1-2610) — AInvest Wire, Oct 11, 2026
  BridgeBio Pharma’s Calcilytix Therapeutics recently announced topline results from its Phase 3 CALIBRATE trial of encaleret, an oral therapy under development for individuals with autosomal dominant hypocalcemia type 1 . The trial demonstrated that encaleret increased bone turnover and improved…
- [BridgEBio announces FDA acceptance & priority review of NDA for](https://www.ainvest.com/news/bridgebio-announces-fda-acceptance-priority-review-nda-2610) — AInvest Wire, Oct 6, 2026
- [BBP-418 demonstrates potential to be disease modifying therapy, restoring cardiac and disease markers to unaffected levels](https://www.ainvest.com/news/bbp-418-demonstrates-potential-disease-modifying-therapy-restoring-cardiac-disease-markers-unaffected-levels-2610) — AInvest Wire, Oct 5, 2026
  BridgeBio Pharma has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for BBP-418, an oral small molecule therapy for Limb-Girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9), a rare, progressive neuromuscular disorder caused by mutations in the FKRP gene. The NDA…
- [BridgEBio: Attriby cuts Diretic intensification risk 43%](https://www.ainvest.com/news/bridgebio-attriby-cuts-diretic-intensification-risk-43-2609) — AInvest Wire, Sep 23, 2026
  BridgeBio Pharma, Inc. (Nasdaq: BBIO) has reported that its drug Attruby (acoramidis) is associated with 43% reduction in outpatient diuretic intensification compared to tafamidis, according to a real-world study. This finding is part of a broader set of data demonstrating the clinical benefits of…
- [Bridgebio Oncology Therapeutics Inc: Leerink partners cuts target price to $27 from $39](https://www.ainvest.com/news/bridgebio-oncology-therapeutics-leerink-partners-cuts-target-price-27-39-2609) — AInvest Wire, Sep 10, 2026
  Leerink Partners has adjusted its price target for BridgeBio Oncology Therapeutics Inc (NASDAQ:BBOT), reducing it to $27 from a previous $39, according to recent analyst activity. This move reflects a reassessment of the company’s outlook, potentially influenced by evolving dynamics in its oncology…

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).